Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, Giuliano AR, Pilon-Thomas S. Dukes CW, et al. Among authors: leav b. Vaccines (Basel). 2023 Dec 22;12(1):13. doi: 10.3390/vaccines12010013. Vaccines (Basel). 2023. PMID: 38250826 Free PMC article.
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge.
Baden LR, El Sahly HM, Essink B, Follmann D, Neuzil KM, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Schödel F, Pajon R, Zhou H, Das R, Miller J. Baden LR, et al. Among authors: leav b. medRxiv [Preprint]. 2021 Sep 22:2021.09.17.21263624. doi: 10.1101/2021.09.17.21263624. medRxiv. 2021. PMID: 34611666 Free PMC article. Updated. Preprint.
Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Giuliano A, et al. Among authors: leav b. Cancer Commun (Lond). 2023 Jul;43(7):749-764. doi: 10.1002/cac2.12453. Epub 2023 Jun 28. Cancer Commun (Lond). 2023. PMID: 37377402 Free PMC article.
No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial.
Naficy A, Kuxhausen A, Seifert H, Hastie A, Leav B, Miller J, Anteyi K, Mwakingwe-Omari A. Naficy A, et al. Among authors: leav b. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327736. doi: 10.1080/21645515.2024.2327736. Epub 2024 Mar 21. Hum Vaccin Immunother. 2024. PMID: 38513689 Free PMC article. Clinical Trial.
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine - An Interim Analysis.
Anderson E, Jackson L, Rouphael N, Widge A, Montefiori D, Doria-Rose N, Suthar M, Cohen K, O'Connell S, Makowski M, Makhene M, Buchanan W, Spearman P, Creech CB, O'Dell S, Schmidt S, Leav B, Bennett H, Pajon R, Posavad C, Hural J, Beigel J, Albert J, Abebe K, Eaton A, Rostad C, Rebolledo P, Kamidani S, Graciaa D, Coler R, McDermott A, Ledgerwood J, Mascola J, DeRosa S, Neuzil K, McElrath MJ, Roberts P. Anderson E, et al. Among authors: leav b. Res Sq [Preprint]. 2022 May 3:rs.3.rs-1222037. doi: 10.21203/rs.3.rs-1222037/v1. Res Sq. 2022. PMID: 35547849 Free PMC article. Preprint.
Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants.
Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group; Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott A, Doria-Rose NA. Pegu A, et al. Among authors: leav b. bioRxiv [Preprint]. 2021 May 16:2021.05.13.444010. doi: 10.1101/2021.05.13.444010. bioRxiv. 2021. PMID: 34031659 Free PMC article. Updated. Preprint.
The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Essink B, Chu L, Seger W, Barranco E, Le Cam N, Bennett H, Faughnan V, Pajon R, Paila YD, Bollman B, Wang S, Dooley J, Kalidindi S, Leav B. Essink B, et al. Among authors: leav b. Lancet Infect Dis. 2023 May;23(5):621-633. doi: 10.1016/S1473-3099(22)00764-2. Epub 2023 Jan 19. Lancet Infect Dis. 2023. PMID: 36682364 Clinical Trial.
No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial.
Naficy A, Kuxhausen A, Pirrotta P, Leav B, Miller J, Anteyi K, Danier J, Breuer T, Mwakingwe-Omari A. Naficy A, et al. Among authors: leav b. Clin Infect Dis. 2023 Nov 11;77(9):1238-1246. doi: 10.1093/cid/ciad361. Clin Infect Dis. 2023. PMID: 37335963 Free PMC article. Clinical Trial.
Stochastic interventional approach to assessing immune correlates of protection: Application to the COVE messenger RNA-1273 vaccine trial.
Hejazi NS, Shen X, Carpp LN, Benkeser D, Follmann D, Janes HE, Baden LR, El Sahly HM, Deng W, Zhou H, Leav B, Montefiori DC, Gilbert PB. Hejazi NS, et al. Among authors: leav b. Int J Infect Dis. 2023 Dec;137:28-39. doi: 10.1016/j.ijid.2023.09.012. Epub 2023 Oct 25. Int J Infect Dis. 2023. PMID: 37820782 Free PMC article. Clinical Trial.
55 results